J Korean Med Sci.  2011 Sep;26(9):1159-1164. 10.3346/jkms.2011.26.9.1159.

Safety of Accelerated Schedules of Subcutaneous Allergen Immunotherapy with House Dust Mite Extract in Patients with Atopic Dermatitis

• Kim ME
• Kim JE
• Sung JM
• Lee JW
• Choi GS
• Nahm DH

• KMID: 1779388
• DOI: http://doi.org/10.3346/jkms.2011.26.9.1159

Abstract

The safety of accelerated schedules of allergen immunotherapy (ASAI) in patients with bronchial asthma (BA) has been reported but there are little data on the safety of ASAI for patients with atopic dermatitis (AD). In this study, we investigated the safety of ASAI in patients with AD. Sixty patients with AD and 18 patients with BA sensitized to house dust mites (HDM) were studied. A maximum maintenance dose of HDM extract, adsorbed to aluminum hydroxide, was administered to patients by subcutaneous injection with either a 3-day protocol (rush immunotherapy) or 1-day protocol (ultra-rush immunotherapy). Systemic reactions were observed 4 of 15 patients (26.7%) with AD during rush immunotherapy, 13 of 45 patients (28.9%) with AD during ultra-rush immunotherapy, and 4 of 18 patients (22.2%) with BA during rush immunotherapy (P > 0.05). No severe or near fatal systemic reactions occurred in 78 subjects of this study. Systemic reactions developed within 4 hr after administration of the maximum allergen dose in 20 of 21 patients (95.2%) with AD and BA who showed systemic reactions during rush or ultra-rush immunotherapy. In conclusion, ASAI was safe and well tolerated in patients with AD. ASAI can be a useful therapeutic option for AD.

Keyword

Allergens; Desensitization; Dermatitis, Atopic; Bronchial Asthma; Adverse Effects; Dermatophagoides; Pyroglyphidae

MeSH Terms

Adolescent
Adult
Allergens/*therapeutic use
Aluminum Hydroxide/chemistry
Animals
Asthma/therapy
Dermatitis, Atopic/immunology/*therapy
Desensitization, Immunologic/*methods
Drug Administration Schedule
Female
Humans
Infusions, Subcutaneous
Male
Pyroglyphidae/*immunology/metabolism

Reference

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998. 102:558–562.

2. Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir Med. 2009. 103:800–812.

3. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006. 97:126–137.

4. Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy. 1994. 73:409–418.

5. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol. 2004. 50:391–404.

6. Platts-Mills TA, Mitchell EB, Rowntree S, Chapman MD, Wilkins SR. The role of dust mite allergens in atopic dermatitis. Clin Exp Dermatol. 1983. 8:233–247.

7. Tupker RA, De Monchy JG, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol. 1996. 97:1064–1070.

8. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of house dust-mite allergen avoidance on atopic dermatitis. Lancet. 1996. 347:15–18.

9. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007. 7:542–546.

10. Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J, Kapp A. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006. 61:202–205.

11. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011. 127:1 Suppl. S1–S55.

12. Hanifin JM, Rajka G. Diagnostic features of atopic eczema. Acta Derm Venereol (Stockh). 1980. 92:44–47.

13. Malling HJ, Weeke B. Immunotherapy: Position paper of the European Academy of Allergology and Clinical Immunology. Allergy. 1993. 48:Suppl 14. 9–35.

14. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008. 31:143–178.

15. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, Valovirta E. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007. 62:317–324.

16. Casanovas M, Martín R, Jiménez C, Caballero R, Fernández-Caldas E. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts. Clin Exp Allergy. 2007. 37:434–440.

17. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Ohno Y, Yamada K, Nasako Y. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta Otolaryngol Suppl. 1998. 538:113–117.

18. Ruëff F, Wolf H, Schnitker J, Ring J, Przybilla B. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy. 2004. 59:589–595.

19. Müller UR. Venom immunotherapy: aqueous vs aluminium hydroxide adsorbed extracts. Allergy. 2004. 59:577–578.

20. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy. 2006. 36:254–260.

21. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006. 117:134–140.

22. Casanovas M, Martín R, Jiménez C, Caballero R, Fernández-Caldas E. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol. 2006. 139:153–158.

23. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T. European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006. 118:152–169.

24. Lower T, Henry J, Mandik L, Janosky J, Friday GA Jr. Compliance with allergen immunotherapy. Ann Allergy. 1993. 70:480–482.

25. Mueller RS, Bettenay SV. Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. Am J Vet Res. 2001. 62:307–310.

26. Trimmer AM, Griffin CE, Boord MJ, Rosenkrantz WS. Rush allergen specific immunotherapy protocol in feline atopic dermatitis: a pilot study of four cats. Vet Dermatol. 2005. 16:324–329.